Low-dose eye drops can manage adult myopia for 24 hours
May 4, 2026
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia.
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia.
A new study published in The Journal of Prevention of Alzheimer’s Disease suggests that these oral capsules may actually be linked to a faster decline in cognitive function.
Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s Faslodex but showed no such significant benefit in the intention-to-treat analysis.
Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.
https://medtechspectrum.com/news/40/25517/unm-scientist-studies-where-brain-cancer-cells-hide-and-how-to-fight-them.html
Scientists have developed a way to turn the body’s own immune cells into cancer-fighting agents—without removing them from the body—by using red blood cells to deliver genetic instructions.
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers.
The U.S. Food and Drug Administration has approved Merck’s Idvynso (doravirine/islatravir), a new, once-daily, two-drug single tablet for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL).
Establishing it as the first ever reusable intermittent urinary catheter system and creating a new device classification in an industry that exclusively relied on single-use catheters for decades
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.